StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Vectibix (panitumumab by Quarter

Vectibix (panitumumab — Metastatic Colorectal Cancer) — U.S. product sales ($M) ($M)

QuarterlyAnnual

Amgen Vectibix (panitumumab: $167M in Q2 2026, up 16.0% from a year earlier. That is the highest of the 32 quarters on record here.

Latest, Q2 2026
167
Period ended Jun 30, 2026
Change on a year earlier
+16.0%
144 in Q2 2025
History
32 quarters
Since Q3 2018
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVectibix (panitumumab — Metastatic Colorectal Cancer) — U.S. product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026167+16.0%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026136+0.7%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025163+21.6%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025162+22.7%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025144+8.3%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025135+12.5%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024134+15.5%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024132+13.8%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024133+12.7%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024120+8.1%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023116+6.4%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023116+9.4%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023118+22.9%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023111+30.6%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022109+18.5%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022106+26.2%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Cite this data

StockData. (2026). Amgen Vectibix (panitumumab ($M), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-vectibix-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.